Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 16, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $23 on, Feb 16th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $23 on, Feb 16th, 2023.
Raghuram has made no other calls on URGN in the last 4 months.
There is 1 other peer that has a rating on URGN. Out of the 1 peers that are also analyzing URGN, all agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $10 on, Wednesday, February 8th, 2023
